GSK unveils positive trial results for vaccine against RSV
21st Jun 2023 09:19
(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.
Read moreFDA extends review period of GSK blood cancer drug momelotinib
16th Jun 2023 07:47
(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.
Read moreGSK gets European approval for RSV vaccine
7th Jun 2023 07:34
(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.
Read moreUS FDA accepts GSK supplemental application for Jemperli cancer drug
6th Jun 2023 07:18
(Sharecast News) - GSK said the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application for its Jemperli treatment of adults with primary advanced or recurrent endometrial cancer.
Read moreCanadian court dismisses GSK Zantac litigation
12th May 2023 08:32
(Sharecast News) - A proposed class action against GSK has been dismissed by a court in Canada, the UK drugs giant confirmed on Friday.
Read moreGSK sells 2.4% of Haleon stake via placing for £804m
12th May 2023 07:52
(Sharecast News) - UK pharmaceuticals company GSK said it had sold a 2.5% stake in Haleon at 335p a share, raising £804m.
Read moreEMA adopts 'positive opinion' of GSK's RSV vaccine candidate
27th Apr 2023 08:16
(Sharecast News) - GSK updated the market on its respiratory syncytial virus (RSV) vaccine candidate for older adults on Thursday, reporting that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion by consensus.
Read moreGSK Q1 beats estimates
26th Apr 2023 07:38
(Sharecast News) - GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
Read moreGSK says EMA validates cancer drug submission
25th Apr 2023 08:03
(Sharecast News) - GSK said the European Medicines Agency had validated the its submission for a potential new indication of its treatment for a type of gynaecological cancer known as mismatch repair deficient primary advanced or recurrent endometrial cancer.
Read moreGSK 'sticks two fingers up' as workers vote for strike action
19th Apr 2023 12:36
(Sharecast News) - Pharmaceuticals giant GSK is set to face a series of walkouts throughout May, it emerged on Wednesday, as hundreds of its workers who are members of the Unite union voted for strike action over a pay dispute.
Read moreGSK to buy Canada's Bellus Health for $2bn
18th Apr 2023 07:52
(Sharecast News) - Pharmaceutical company GSK is buying Canadian drug development company Bellus Health for $2bn in cash, the companies said on Tuesday.
Read moreGSK announces positive results from trials of new UTI antibiotic
17th Apr 2023 09:08
(Sharecast News) - GSK has announced positive results from trials of a potential new antibiotic treatment for urinary tract infections on Monday.
Read moreGSK receives 'positive' results from endometrial cancer drug trial
28th Mar 2023 08:03
(Sharecast News) - Pharmaceutical giant GSK revealed on Tuesday that a recent trial on its endometrial cancer drug candidate showed the potential of the medication when used alongside chemotherapy.
Read moreGSK disagrees with ranitidine evidence ruling in California
24th Mar 2023 10:33
(Sharecast News) - Pharmaceuticals giant GSK responded to a recent ruling in the ongoing legal wranglings over its now-suspended blockbuster heartburn drug Zantac on Friday.
Read moreDeutsche Bank upgrades GSK to 'buy'
17th Mar 2023 12:14
(Sharecast News) - Analysts at Deutsche Bank upgraded biopharmaceutical firm GSK from 'hold' to 'buy' on Friday as they updated estimates and made changes to their net present value assumptions.
Read more